Preprocedural statin use in patients undergoing percutaneous coronary intervention

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Current guidelines recommend statin administration before percutaneous coronary interventions (PCIs).
• Previous studies suggest statins may reduce risks of periprocedural myocardial infarction and contrast-induced nephropathy.
• The real-world adherence to these guidelines and its impact on patient outcomes remain unclear.

Purpose of the Study:

• To investigate the incidence of statin pretreatment in patients undergoing PCI.
• To evaluate the association between statin pretreatment and in-hospital outcomes.
• To assess the long-term mortality impact of statin pretreatment in PCI patients.

Main Methods:

• Analysis of 80,493 patients from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium PCI registry (2010-2012).
• Utilized propensity and exact matching to control for non-random statin use.
• Linked a subset of patients to Medicare data to assess long-term survival.

Main Results:

• 33% of patients did not receive statins prior to PCI.
• Matched analysis showed no significant difference in in-hospital mortality (0.43% vs 0.42%) or periprocedural myocardial infarction (2.34% vs 2.10%) between statin non-receivers and receivers.
• No differences observed in rates of coronary artery bypass grafting, cerebrovascular accident, or contrast-induced nephropathy.
• No association found between pre-PCI statin use and long-term survival.

Conclusions:

• A substantial proportion of patients undergoing PCI do not receive statin pretreatment.
• Absence of statin pretreatment was not linked to increased in-hospital major complications.
• Pre-PCI statin use showed no association with long-term mortality in this cohort.